The Regulator

$2 billion: that is how much in Medicaid funding the Trump administration has now deferred from California, citing “suspected fraud and noncompliance,” as the state’s hospice fraud crisis grinds into its second year. Federal officials and California are locked in an escalating fight over hospice and home health fraud, the Associated Press reported today, after the Centers for Medicare and Medicaid Services (CMS) imposed a six-month nationwide moratorium on new Medicare hospice and home health enrollments effective May 13, 2026, working with the White House’s Anti-Fraud Task Force. More than 1,000 California hospices have lost their Medicare billing privileges since early 2025, shrinking the state’s hospice count to roughly 2,100 from 2,800 four years ago, while California Attorney General Rob Bonta has filed more than 100 criminal cases and secured over 50 convictions since a 2021 provider moratorium, revoking about 500 licenses. Los Angeles County alone accounts for an estimated $3.5 billion in fraudulent hospice claims, and patients like 71 year old retiree Linda Henry, fraudulently enrolled at a Fortuna Hospice Inc. facility in 2024, have spent months proving they were never dying just to resume normal medical care, since Medicare will not pay for treatment outside hospice once someone is enrolled. Confidence: Medium. This account combines CMS’s own moratorium announcement with wire reporting on the escalating dollar figures and victim accounts, since no single agency document dated this week disclosed the $2 billion deferral total. Sources: CMS nationwide hospice and home health enrollment moratorium announcement, Centers for Medicare and Medicaid Services, AP Health News wire report, Bangor Daily News.

$5 million: that is what a melanoma testing company now liquidating in bankruptcy will pay after admitting it kept billing Medicare for skin cancer tests it knew had failed quality control. The Department of Justice announced August 25, 2026 that DermTech Inc., now known as DTech Liquidating Inc. after a June 2024 Chapter 11 filing, resolved False Claims Act allegations that from October 2022 through March 2023 it billed Medicare for its melanoma marker skin tests after switching to an unvalidated positive control range for one of the test’s two key genetic markers, then neither retracted the affected results nor refunded Medicare once the problem surfaced. The settlement resolves as a $5,038,011 allowed unsecured claim in DermTech’s bankruptcy proceeding, and a whistleblower who first raised the alarm will collect a share under the False Claims Act’s qui tam provisions. Confidence: Medium. Justice.gov’s own press release page returned an access error to direct fetch this run, a recurring pattern with DOJ; this account relies on the release’s indexed text and corroborating legal trackers. Sources: DermTech Inc. to Pay Up to $5M to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer Tests, U.S. Department of Justice.

Two of three: that is how many Arizona Medicaid insurers a federal watchdog says could not even prove they were following the law requiring equal treatment for mental health claims. The HHS Office of Inspector General (OIG) found Arizona failed to ensure its Medicaid managed care insurers complied with federal mental health and substance use disorder parity requirements on prior authorization, reviewing data from October 2022 through September 2023 covering three of nine insurers that together serve about 58 percent of Arizona’s 1.9 million Medicaid managed care enrollees; two of the three could not produce reliable prior authorization data to demonstrate compliance, and state oversight itself was hampered by unclear, contradictory written policies. Arizona is the third state in this OIG audit series to show the same failure, following earlier reports on Kansas and New York, suggesting the prior authorization limits that can delay or deny addiction and mental health treatment are going largely unchecked nationally. Confidence: Medium. OIG’s own report page could not be independently located this run; this account relies on trade press review of the report’s findings. Sources: Arizona failed to ensure Medicaid insurers followed mental health parity rules, Becker’s Behavioral Health.

13 months versus 6.7: that is the survival gap the Food and Drug Administration says justifies approving the first drug built to directly target the mutation driving 90 percent of pancreatic cancers. The FDA approved daraxonrasib (brand name Rasonque) August 26, 2026 for adults with metastatic pancreatic adenocarcinoma who have already tried one prior treatment or cannot tolerate combination chemotherapy, clearing the drug roughly six and a half months ahead of its target decision date. In the pivotal RASolute 302 trial of 500 patients, those on daraxonrasib had a median overall survival of just over 13 months, compared with 6.7 months on standard chemotherapy, the first clinical evidence that directly blocking the RAS protein family can meaningfully extend life in this cancer. Confidence: High. This run reviewed the FDA’s own drug approval page directly. Sources: FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma, U.S. Food and Drug Administration.

14 states: that is how many received intravenous saline bags Baxter says may contain shards of fiberglass. Baxter International issued a voluntary nationwide recall of two lots of 0.9 percent Sodium Chloride Injection, packaged in 500 milliliter Viaflex bags, after finding fiberglass particulate matter in the solution; the affected lots shipped between July 31 and August 3, 2026 to hospitals and distributors in Florida, Illinois, Indiana, Louisiana, Maryland, Missouri, North Carolina, New Jersey, Nevada, New York, Ohio, South Carolina, Texas, and Virginia. The FDA warns that infusing particulate matter intravenously can block blood vessels, cause a pulmonary embolism, or lead to permanent organ damage or death; as of the August 25, 2026 notice, Baxter had not received any reports of patient harm. Confidence: High. This run reviewed the FDA’s own recall notice directly. Sources: Baxter Issues Voluntary Nationwide Recall for Two Lots of 0.9% Sodium Chloride Injection, U.S. Food and Drug Administration.

$160 million: that is what Alaska just received to send drones loaded with prescriptions to villages where winter deliveries can take two weeks. The Centers for Medicare and Medicaid Services awarded Alaska $160 million across 142 projects under the federal Rural Health Transformation Program, the same $50 billion, five year program that funded Alabama’s first grants on August 24, as part of Alaska’s overall $1.36 billion five year allocation. The money funds a $250,000 drone based pharmacy delivery system for communities spread across 94,000 square miles, more than $3.1 million for artificial intelligence stroke detection imaging across 21 acute care hospitals, $6.5 million for the state’s first robotic assisted surgery program in Southern Southeast Alaska, and $5 million for a tribally led residential addiction treatment campus. Confidence: Medium. CMS’s newsroom page returned an access error to direct fetch this run; this account is corroborated by Alaska’s own state health department documentation of the funded initiatives. Sources: Alaska Rural Health Transformation Program initiatives, Alaska Department of Health, Rural Health Transformation Program overview, Centers for Medicare and Medicaid Services.

$1.4 million: that is what a rural Minnesota hospital must refund or forgive after state investigators found it overcharged uninsured patients by as much as 20.5 percent. Minnesota Attorney General Keith Ellison announced a settlement August 10, 2026 with Stevens Community Medical Center in Morris, Minnesota, after finding the hospital miscalculated the discounts state law requires for uninsured patients between April 1, 2020 and December 31, 2025, resulting in some patients being billed up to 20.5 percent more than Minnesota law allows. Roughly 3,500 patients with household income under $125,000 during that period are eligible for refunds or medical debt cancellation totaling up to $1,412,776.25, and the hospital must notify every affected patient directly. Confidence: High. This run reviewed the Minnesota Attorney General’s own press release directly. Sources: Attorney General Ellison secures debt relief for Stevens Community Medical Center patients, Minnesota Attorney General’s Office.